SUNNYVALE, Calif., Dec. 6 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. announced today a presentation and multiple published abstracts regarding Xcytrin(R) (motexafin gadolinium) Injection. The presentation and publications are part of the proceedings at the American Society of Hematology (ASH) 47th Annual Meeting and Exposition being held December 10-13, 2005, at the Georgia World Congress Center in Atlanta, GA. The company will have booth #334 in the Exhibit Hall.
The presentation and published abstracts are as follows: Sunday, December 11, 2005 Poster Session 654-II
Title: Combination of Motexafin Gadolinium (MGd) with 90Y Ibritumomab Tiuxetan (Zevalin(R); 90Yttrium-Zevalin) Radioimmunotherapy (RIT) Produces High Complete Remission Rates in Relapsed Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma (NHL).
Abstract #2450: 9:15 a.m. Motexafin Gadolinium Published Abstracts Abstract #4275
Title: Motexafin Gadolinium Upregulates pAkt Levels and Synergizes with Inhibitors of Akt Phosphorylation
Abstract #4296
Title: Growth Inhibition or Apoptosis after Treatment with Motexafin Gadolinium and Celecoxib Is Cell Line Dependent and Correlates with p27 Levels
Abstract #4468
Title: Motexafin Gadolinium and Other Metallotexaphyrins Upregulate Heme Oxygenase-1
Abstract #4758
Title: Motexafin Gadolinium (MGd) Has Clinical Activity in Relapsed/Refractory Low Grade Lymphomas (LG) and Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Abstract #4827
Title: Motexafin Gadolinium Causes Apoptosis in Lymphoma Cells by Increasing Intracellular Free Zinc and Disrupting Redox Balance
Abstract #4829
Title: Motexafin Gadolinium Enhances Rituximab-Induced Cytotoxicity Against B-Cell Lymphoma Cell Lines: Role of Elevated Intracellular Calcium
About Xcytrin
Pharmacyclics is developing Xcytrin as an anti-cancer agent with a novel mechanism of action that is designed to selectively concentrate in tumors and induce apoptosis (programmed cell death). Xcytrin is a redox active drug that disrupts redox dependent pathways in cells and inhibits oxidative stress related proteins. Its multifunctional mode of action provides the opportunity to be used in a broad range of cancers. Xcytrin is paramagnetic and produces an intense MRI signal which can be used to image tumors. Pharmacyclics has been granted Fast-Track status by the U.S. Food and Drug Administration (FDA) for Xcytrin for the treatment of brain metastases (cancer that has spread to the brain from another part of the body) in patients with non-small cell lung cancer (NSCLC). Xcytrin is currently being evaluated in a randomized Phase 3 clinical trial (the SMART trial) that completed enrollment earlier this year and is designed to compare the effects of whole brain radiation therapy (WBRT) alone to WBRT plus Xcytrin for the treatment of brain metastases in patients suffering from NSCLC. Xcytrin also is currently under investigation in several Phase 1 and Phase 2 clinical trials in various cancers evaluating its use as a single agent and in combination with chemotherapy and/or radiation therapy.
About Pharmacyclics
Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and atherosclerosis. The company’s products are rationally designed, ring-shaped small molecules called texaphyrins that are designed to selectively target and disrupt the bioenergetic processes of diseased cells, such as cancer and atherosclerotic plaque. More information about the company, its technology, and products in development can be found on its website at www.pharmacyclics.com. Pharmacyclics(R), Xcytrin(R) and the “pentadentate” logo(R) are registered trademarks of Pharmacyclics, Inc.
NOTE: Zevalin(R) is a registered trademark of Biogen Idec.
Pharmacyclics, Inc.
CONTACT: Leiv Lea of Pharmacyclics, Inc., +1-408-774-0330; or CarolynBumgardner Wang of WeissComm Partners, +1-415-946-1065, for Pharmacyclics,Inc.
Web site: http://www.pharmacyclics.com/
